Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
News releases from Adaptimmune Therapeutics plc
< Previous
1
2
3
4
5
6
Next >
Adaptimmune Announces Succession Plan for Chairman at End of 2016
May 24, 2016
Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in T-cell therapy to treat cancer, today announced a succession plan for the Chairmanship position that will take...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune Strengthens Board with Appointment of Barbara Duncan
May 24, 2016
Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in T-cell therapy to treat cancer, today announced the appointment of Barbara Duncan to its Board of Directors as...
Tickers
ADAP
ICPT
MDGN
From
GlobeNewswire News Releases
Adaptimmune to Present at the 2016 UBS Global Healthcare Conference
May 19, 2016
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present at the 2016 UBS Global...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune Reports First Quarter 2016 Financial Results
May 12, 2016
Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in T-cell therapy to treat cancer, today reported financial results for the first quarter ended March 31, 2016.
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
May 03, 2016
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Adrian Rawcliffe, Chief Financial Officer of Adaptimmune, will present at the Bank of...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune to Present at the Deutsche Bank Securities 41st Annual Health Care Conference
April 27, 2016
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune Presents Corporate and Clinical Updates at Investor and Analyst Day
April 22, 2016
Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today hosted an Investor and Analyst meeting in New York and presented clinical and...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune Announces SPEAR T-cells™ Brand for Proprietary Technology
April 22, 2016
Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the company has adopted the name SPEAR T-cells™ (Specific Peptide...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune Appoints Leading Immunotherapy Experts from United States and Europe to Inaugural Scientific Advisory Board
April 22, 2016
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced the appointment of leading immunology, immunotherapy and oncology...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune to Host Analyst and Investor Day on April 22, 2016
April 20, 2016
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the company will host a live webcast in conjunction with its 2016...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune Announces New Vice President of Business Development, Wenyong Wang
April 18, 2016
Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that Dr. Wenyong Wang has joined the company as Vice President of...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting AFP in Liver Cancer
April 07, 2016
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has accepted the...
Tickers
ADAP
From
GlobeNewswire News Releases
U.S. Food and Drug Administration Grants Orphan Drug Designation to Adaptimmune’s T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma
March 30, 2016
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration (FDA)'s Office of Orphan...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune Reports Financial Results for the Six-Month Period ended December 31, 2015
March 17, 2016
Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in the use of T-cell therapy to treat cancer, today reported financial results for the six-month period ended...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune to Present at Cowen and Company’s 36th Annual Health Care Conference
March 02, 2016
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune to Present at the RBC Capital Markets Global Healthcare Conference
February 17, 2016
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present...
Tickers
ADAP
From
GlobeNewswire News Releases
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Adaptimmune’s Affinity Enhanced T-cell Therapy Targeting NY-ESO in Synovial Sarcoma
February 09, 2016
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune to Participate in Two Upcoming Investor Conferences
February 03, 2016
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune to Host Conference Call at 10:00 AM ET (3:00 PM GMT) Today (Tuesday, February 2) to Discuss Expansion of Strategic Collaboration Agreement with GlaxoSmithKline (GSK)
February 02, 2016
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, will host a live teleconference and webcast at 10:00 a.m. Eastern Time (3:00 p.m. GMT)...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration
February 02, 2016
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of T- cell receptor (TCR) engineered T-cell therapy to treat cancer, and GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) today announced that...
Tickers
ADAP
GSK
From
GlobeNewswire News Releases
Adaptimmune Announces New Additions to Manufacturing Senior Management
January 22, 2016
Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it has augmented its manufacturing leadership to prepare for...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune Expands T-cell Engineering Expertise to Develop Affinity Enhanced T-cell Therapies for Autoimmune Indications
January 07, 2016
Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it is expanding its T-cell therapy development activities to...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune Announces Initiation of Study to Evaluate its New Affinity Enhanced T-Cell Therapy Targeting MAGE-A10 in Patients With NSCLC, the Most Common Form of Lung Cancer
December 17, 2015
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it has initiated a Phase I/II study of its affinity enhanced...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune Wins Scrip Award for Financing Deal of the Year
December 03, 2015
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it has won the Financing Deal of the Year Award at the 2015 Scrip...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune and Universal Cells Announce Collaboration to Develop Allogeneic T-Cell Therapies
November 30, 2015
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, and Seattle-based Universal Cells Inc., a genome editing company developing universal...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune Initiates Phase I / II Trial Evaluating Its Affinity Enhanced T-Cell Therapy Targeting NY-ESO-1 in Patients With the Most Common Type of Lung Cancer
November 24, 2015
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of engineered T-cell therapy to treat cancer, today announced that it has initiated a study of its affinity enhanced T-cell therapy...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune Reports First Quarter Financial Results for Fiscal Year 2015-16
November 12, 2015
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of T-cell therapy to treat cancer, today reported financial results for the first quarter, which ended September 30, 2015.
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune to Participate in the Jefferies Autumn 2015 Global Healthcare Conference
November 12, 2015
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present at the...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune Announces Data From Clinical Study of NY-ESO Affinity Enhanced T-Cell Therapy in Synovial Sarcoma at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer (SITC)
November 05, 2015
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today presents updated data on its lead clinical program, an affinity enhanced T-cell...
Tickers
ADAP
From
GlobeNewswire News Releases
Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer (SITC)
October 30, 2015
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that it will present new data from trials of...
Tickers
ADAP
From
GlobeNewswire News Releases
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.